Fang Wang, Kai Fu, Yujue Wang, Can Pan, Xueping Wang, Zeyu Liu, Chuan Yang, Ying Zheng, Xiaopeng Li, Yu Lu, Kenneth Kin Wah To, Chenglai Xia, Jianye Zhang, Zhi Shi, Zeping Hu, Min Huang, Liwu Fu
Cancer immunotherapy, exemplified by the remarkable clinical benefits of the immune checkpoint blockade and chimeric antigen receptor T-cell therapy, is revolutionizing cancer therapy. They induce long-term tumor regression and overall survival benefit in many types of cancer. With the advances in our knowledge about the tumor immune microenvironment, remarkable progress has been made in the development of small-molecule drugs for immunotherapy. Small molecules targeting PRR-associated pathways, immune checkpoints, oncogenic signaling, metabolic pathways, cytokine/chemokine signaling, and immune-related kinases have been extensively investigated...
March 2024: Acta Pharmaceutica Sinica. B